2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Parkinson's disease associated mutations in leucine rich repeat kinase 2 (LRRK2) impair mitochondrial function and increase the vulnerability of induced pluripotent stem cell (iPSC)-derived neural cells from patients to oxidative stress. Since mitochondrial DNA (mtDNA) damage can compromise mitochondrial function, we examined whether LRRK2 mutations can induce damage to the mitochondrial genome. We found greater levels of mtDNA damage in iPSC-derived neural cells from patients carrying homozygous or heterozygous LRRK2 G2019S mutations, or at-risk individuals carrying the heterozygous LRRK2 R1441C mutation, than in cells from unrelated healthy subjects who do not carry LRRK2 mutations. After zinc finger nuclease-mediated repair of the LRRK2 G2019S mutation in iPSCs, mtDNA damage was no longer detected in differentiated neuroprogenitor and neural cells. Our results unambiguously link LRRK2 mutations to mtDNA damage and validate a new cellular phenotype that can be used for examining pathogenic mechanisms and screening therapeutic strategies.

          Related collections

          Author and article information

          Journal
          Neurobiol. Dis.
          Neurobiology of disease
          Elsevier BV
          1095-953X
          0969-9961
          Feb 2014
          : 62
          Affiliations
          [1 ] Pittsburgh Institute for Neurodegenerative Diseases, Department of Neurology, University of Pittsburgh, Pittsburgh, PA 15260, USA.
          [2 ] Sangamo BioSciences, Inc., Point Richmond Tech Center, 501 Canal Boulevard, Suite A100, Richmond, CA 94804, USA.
          [3 ] Neuroregeneration Institute, McLean Hospital/Harvard Medical School, Belmont, MA 02478, USA.
          [4 ] The Parkinson's Institute, 675 Almanor Avenue, Sunnyvale, CA 94025, USA.
          [5 ] Pittsburgh Institute for Neurodegenerative Diseases, Department of Neurology, University of Pittsburgh, Pittsburgh, PA 15260, USA. Electronic address: jgreena@pitt.edu.
          [6 ] Neuroregeneration Institute, McLean Hospital/Harvard Medical School, Belmont, MA 02478, USA. Electronic address: isacson@hms.harvard.edu.
          [7 ] The Parkinson's Institute, 675 Almanor Avenue, Sunnyvale, CA 94025, USA. Electronic address: bschuele@thepi.org.
          Article
          S0969-9961(13)00288-X NIHMS534290
          10.1016/j.nbd.2013.10.013
          3877733
          24148854
          993d2c68-a780-4a02-9420-cd887e083e53
          History

          LRRK2,Mitochondrial DNA damage,Parkinson's disease,Stem cells

          Comments

          Comment on this article